Chong Kun Dang Pharmaceutical Corp.
Symboli: 185750.KS
KSC
101200
KRWMarkkinahinta tänään
6.4696
P/E-suhde
-0.0542
PEG-suhde
1.29T
MRK Cap
- 0.01%
DIV Tuotto
Chong Kun Dang Pharmaceutical Corp. (185750-KS) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 365065.3 | 155861.2 | 187332.6 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 145418.9 | 38444.3 | 55519.9 | |||||||||||
balance-sheet.row.net-receivables | 0 | 311468.6 | 287306.6 | 234703.7 | |||||||||||
balance-sheet.row.inventory | 0 | 261431.9 | 270081.5 | 224722.9 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 8606.1 | 365.5 | 20387.9 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 946571.9 | 713614.8 | 667147.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 319787.1 | 310697.4 | 298909.7 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 67179.1 | 5565.5 | -22146.7 | |||||||||||
balance-sheet.row.tax-assets | 0 | 14213.2 | 6208.6 | 2350.3 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2150.1 | 61843.5 | 79634.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 455856.6 | 411268 | 379552.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.account-payables | 0 | 183938.8 | 145436.3 | 129327.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 184767.4 | 124445.5 | 102091.4 | |||||||||||
balance-sheet.row.tax-payables | 0 | 43938.2 | 29026.4 | 18701.1 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 30000 | 111292.6 | 134962.3 | |||||||||||
Deferred Revenue Non Current | 0 | 1484.8 | 6438.3 | 5982 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 134996.6 | 98922.3 | 20691.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 75327.4 | 129380.9 | 160660.6 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 4996.5 | 1694.2 | 3470.5 | |||||||||||
balance-sheet.row.total-liab | 0 | 586793.3 | 503594 | 480890.4 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 31421.2 | 29970.1 | 28565.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | 218102.4 | 376370.8 | 302106.6 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 350829.8 | 276706.4 | 250156.9 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 215341.1 | -60654.3 | -14818.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 815694.5 | 622393.1 | 566010 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | -59.3 | -1104.3 | -200.3 | |||||||||||
balance-sheet.row.total-equity | 0 | 815635.2 | 621288.8 | 565809.6 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 212598 | 44009.8 | 33373.2 | |||||||||||
balance-sheet.row.total-debt | 0 | 219763.9 | 235738.1 | 237053.8 | |||||||||||
balance-sheet.row.net-debt | 0 | 117.5 | 118321.2 | 105241.1 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 212521.2 | 79977.8 | 42356.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 36942.2 | 33597.7 | 27481.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 29681.8 | -77299.3 | -71568.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -29559.7 | -51435.9 | -6926 | |||||||||||
cash-flows.row.inventory | 0 | -5980.3 | -54466.2 | -53770.6 | |||||||||||
cash-flows.row.account-payables | 0 | 38583.8 | 15824.5 | -15597.8 | |||||||||||
cash-flows.row.other-working-capital | 0 | 26638 | 12778.2 | 4725.7 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 39014.7 | 31458.4 | 14634.2 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 451.6 | 142.1 | -3448.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -192468.2 | -57181.1 | -61266.4 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 89470 | 44375.6 | 21934.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 39.8 | 347.8 | 3815.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -171312.9 | -65380.3 | -90809.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -22714.6 | -0.3 | -896.2 | |||||||||||
cash-flows.row.common-stock-issued | 0 | -3335.3 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -6025 | -1888.4 | -1935.3 | |||||||||||
cash-flows.row.dividends-paid | 0 | -11608.5 | -11238.8 | -10808.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | -16.5 | -3212.4 | 98778.7 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -43700 | -16339.8 | 85138.9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -917.6 | -410.1 | 920.1 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 102229.4 | -14395.8 | 8153.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 219646.3 | 117416.9 | 131812.7 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 117416.9 | 131812.7 | 123659.1 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 318159.9 | 67734.5 | 12903.9 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 249353.9 | 14669.8 | -38940.5 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1669404.4 | 1488344.7 | 1343559.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1014059.9 | 945705.3 | 847741.1 | |||||||||||
income-statement-row.row.gross-profit | 0 | 655344.5 | 542639.4 | 495818.3 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 408657.6 | 432733.3 | 401059.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1422717.5 | 1378438.7 | 1248800.7 | |||||||||||
income-statement-row.row.interest-income | 0 | 5789.3 | 2139 | 716.2 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 36942.2 | 34919.3 | 18187.3 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 246686.9 | 109906.1 | 94758.7 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 241403 | 97165.1 | 80593.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 27995.7 | 17187.3 | 38237.4 | |||||||||||
income-statement-row.row.net-income | 0 | 212521.2 | 80953.4 | 42720.4 |
Usein kysytty kysymys
Mikä on Chong Kun Dang Pharmaceutical Corp. (185750.KS) taseen loppusumma?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) kokonaisvarat ovat 1402428435512.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on N/A.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.530.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on 19599.181.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.122.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.146.
Mikä on Chong Kun Dang Pharmaceutical Corp. (185750.KS) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 212521171440.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 219763880100.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 408657610015.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 0.000.